Safety, tolerability, and immunogenicity of the ChAdOx1 RVF vaccine against Rift Valley fever among healthy adults in Uganda: a single-centre, single-blind, randomised, placebo-controlled, dose-escalation, phase 1 trial
Authors
Jennifer Serwanga (ORCID: https://orcid.org/0000-0002-6672-3688)
Andrew Abaasa (ORCID: https://orcid.org/0000-0002-6770-5588)
Safety, tolerability, and immunogenicity of the ChAdOx1 RVF vaccine against Rift Valley fever among healthy adults in Uganda: a single-centre, single-blind, randomised, placebo-controlled, dose-escalation, phase 1 trial
Jennifer Serwanga, Andrew Abaasa, Phiona Kaweesi Nabaggala, Violet Ankunda et al.
Citations
1 citations
Journal
The Lancet Infectious Diseases
Topics
Viral Infections and Vectors
Field-Weighted Citation Impact (FWCI)
1.40
article
Safety, tolerability, and immunogenicity of the ChAdOx1 RVF vaccine against Rift Valley fever among healthy adults in Uganda: a single-centre, single-blind, randomised, placebo-controlled, dose-escalation, phase 1 trial
Jennifer Serwanga, Andrew Abaasa, Phiona Kaweesi Nabaggala, Violet Ankunda, Vincent Basajja, Adrian V. S. Hill, Alison M. Lawrie, Alison M. Elliott, Christian Stevns Hansen, Daniel Jenkin, Daniel Wright, Nguyen Tran, Pedro M. Folegatti, Ben Gombe, Florence Nambaziira, Ayoub Kakande, Pontiano Kaleebu, Zacchaeus Anywaine, George M. Warimwe, Peter Ejou, Naboth Tukamwesiga, Tamara Namata, Abu-Baker Ggayi, Antony Kigozi, Wilson Kakeeto, Dora Jocelyn Mulondo
article en
1 citations
Abstract
No abstract available for this paper.
Publication Tag
The Lancet Infectious DiseasesVol. 26(3)
Institutions
Statens Serum Institut (DK), Kenya Medical Research Institute (KE), University of Oxford (GB), London School of Hygiene & Tropical Medicine (GB), Jenner Institute (GB), Uganda Virus Research Institute (UG)